在接受利托那韦增强型阿扎那韦治疗的HIV感染患者中，阿扎那韦与质子泵抑制剂之间缺乏相互作用。 - Suppr | 超能文献

Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.

作者信息

Guiard-Schmid Jean-Baptiste, Poirier Jean-Marie, Bonnard Philippe, Meynard Jean-Luc

出版信息

J Acquir Immune Defic Syndr. 2006 Mar;41(3):393-4; author reply 394. doi: 10.1097/01.qai.0000197075.56397.a5.

DOI:10.1097/01.qai.0000197075.56397.a5

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.在接受利托那韦增强型阿扎那韦治疗的HIV感染患者中，阿扎那韦与质子泵抑制剂之间缺乏相互作用。

J Acquir Immune Defic Syndr. 2006 Mar;41(3):393-4; author reply 394. doi: 10.1097/01.qai.0000197075.56397.a5.

2

Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?接受阿扎那韦治疗的患者使用质子泵抑制剂疗法：禁忌？

J Acquir Immune Defic Syndr. 2006 Mar;41(3):394-6. doi: 10.1097/01.qai.0000192002.23400.6e.

3

Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir.

AIDS. 2005 Nov 4;19(16):1937-8. doi: 10.1097/01.aids.0000189565.87600.4d.

4

Atazanavir: in pediatric patients with HIV-1 infection.阿扎那韦：用于治疗 HIV-1 感染的儿科患者。

Paediatr Drugs. 2012 Apr 1;14(2):131-41. doi: 10.2165/11208550-000000000-00000.

5

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.200毫克阿扎那韦对每日一次给予感染HIV患者的1600/100毫克沙奎那韦和利托那韦的细胞内及血浆药代动力学的影响。

J Antimicrob Chemother. 2006 Nov;58(5):1009-16. doi: 10.1093/jac/dkl379. Epub 2006 Sep 19.

6

External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.评估 HIV-1 感染患者中阿扎那韦血浆暴露的胆红素-阿扎那韦列线图的外部验证。

AAPS J. 2013 Apr;15(2):308-15. doi: 10.1208/s12248-012-9440-8. Epub 2012 Dec 7.

7

Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.低剂量奥美拉唑（每日 20 毫克）对健康受试者中多剂量阿扎那韦利托那韦的药代动力学的影响。

J Clin Pharmacol. 2011 Mar;51(3):368-77. doi: 10.1177/0091270010367651. Epub 2010 May 10.

8

Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.猫爪草与蛋白酶抑制剂阿扎那韦、利托那韦和沙奎那韦之间的相互作用。

Eur J Clin Pharmacol. 2008 Dec;64(12):1235-6. doi: 10.1007/s00228-008-0551-1. Epub 2008 Aug 20.

9

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.阿巴卡韦在未感染和感染人类免疫缺陷病毒（HIV）的患者中，分别在不存在和存在阿扎那韦/利托那韦或洛匹那韦/利托那韦的情况下的血浆药代动力学，反之亦然。

Antivir Ther. 2007;12(5):825-30.

10

Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.阿扎那韦与洛匹那韦联合利托那韦单独或联合使用：药代动力学相互作用及药物暴露预测因素分析

HIV Med. 2008 Apr;9(4):239-45. doi: 10.1111/j.1468-1293.2008.00555.x.

引用本文的文献

1

Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption.进餐效应混淆了抵消雷贝拉唑诱导的胃酸过少导致阿扎那韦吸收减少的尝试。

Pharm Res. 2017 Mar;34(3):619-628. doi: 10.1007/s11095-016-2090-2. Epub 2016 Dec 27.

2

Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy.识别和管理 HIV 患者中的显著药物相互作用：利用现有数据指导治疗的挑战。

Clin Pharmacol Ther. 2010 Nov;88(5):712-9. doi: 10.1038/clpt.2010.130. Epub 2010 Jul 28.

3

Renal transplantation in patients with HIV.HIV 感染者的肾移植。

Nat Rev Nephrol. 2009 Oct;5(10):582-9. doi: 10.1038/nrneph.2009.140.